Brown Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.42M | Sell |
7,653
-121
| -2% | -$56.4K | 0.01% | 591 |
|
|
2025
Q4 | $3.52M | Sell |
7,774
-320
| -4% | -$138K | ﹤0.01% | 595 |
|
|
2025
Q3 | $3.17M | Buy |
8,094
+1,236
| +18% | +$517K | ﹤0.01% | 596 |
|
|
2025
Q2 | $3.05M | Buy |
6,858
+277
| +4% | +$128K | ﹤0.01% | 588 |
|
|
2025
Q1 | $3.19M | Buy |
6,581
+739
| +13% | +$344K | ﹤0.01% | 565 |
|
|
2024
Q4 | $2.35M | Buy |
5,842
+641
| +12% | +$297K | ﹤0.01% | 625 |
|
|
2024
Q3 | $2.42M | Buy |
5,201
+6
| +0.1% | +$2.88K | ﹤0.01% | 623 |
|
|
2024
Q2 | $2.44M | Buy |
5,195
+446
| +9% | +$194K | ﹤0.01% | 598 |
|
|
2024
Q1 | $1.99M | Buy |
4,749
+1,227
| +35% | +$519K | ﹤0.01% | 643 |
|
|
2023
Q4 | $1.43M | Buy |
3,522
+705
| +25% | +$260K | ﹤0.01% | 693 |
|
|
2023
Q3 | $980K | Buy |
2,817
+67
| +2% | +$23.4K | ﹤0.01% | 747 |
|
|
2023
Q2 | $968K | Buy |
2,750
+199
| +8% | +$67K | ﹤0.01% | 754 |
|
|
2023
Q1 | $804K | Buy |
2,551
+330
| +15% | +$99K | ﹤0.01% | 810 |
|
|
2022
Q4 | $641K | Buy |
2,221
+237
| +12% | +$72.2K | ﹤0.01% | 848 |
|
|
2022
Q3 | $574K | Buy |
1,984
+187
| +10% | +$53.8K | ﹤0.01% | 828 |
|
|
2022
Q2 | $507K | Sell |
1,797
-121
| -6% | -$32.4K | ﹤0.01% | 843 |
|
|
2022
Q1 | $501K | Buy |
1,918
+634
| +49% | +$150K | ﹤0.01% | 857 |
|
|
2021
Q4 | $282K | Sell |
1,284
-235
| -15% | -$45.7K | ﹤0.01% | 1053 |
|
|
2021
Q3 | $276K | Sell |
1,519
-534
| -26% | -$104K | ﹤0.01% | 972 |
|
|
2021
Q2 | $413K | Buy |
2,053
+544
| +36% | +$114K | ﹤0.01% | 878 |
|
|
2021
Q1 | $325K | Buy |
1,509
+88
| +6% | +$19.3K | ﹤0.01% | 931 |
|
|
2020
Q4 | $336K | Sell |
1,421
-587
| -29% | -$135K | ﹤0.01% | 857 |
|
|
2020
Q3 | $546K | Buy |
2,008
+378
| +23% | +$104K | ﹤0.01% | 724 |
|
|
2020
Q2 | $473K | Buy |
+1,630
| New | +$442K | ﹤0.01% | 736 |
|
|
2020
Q1 | – | Sell |
-1,020
| Closed | -$223K | – | 1052 |
|
|
2019
Q4 | $223K | Buy |
+1,020
| New | +$206K | ﹤0.01% | 957 |
|
|
2019
Q3 | – | Sell |
-1,439
| Closed | -$263K | – | 1042 |
|
|
2019
Q2 | $263K | Sell |
1,439
-5,109
| -78% | -$893K | ﹤0.01% | 902 |
|
|
2019
Q1 | $1.2M | Buy |
6,548
+147
| +2% | +$27.2K | ﹤0.01% | 768 |
|
|
2018
Q4 | $1.06M | Buy |
6,401
+69
| +1% | +$12K | ﹤0.01% | 753 |
|
|
2018
Q3 | $1.22M | Buy |
6,332
+5
| +0.1% | +$890 | ﹤0.01% | 763 |
|
|
2018
Q2 | $1.07M | Buy |
6,327
+304
| +5% | +$47.1K | ﹤0.01% | 780 |
|
|
2018
Q1 | $981K | Sell |
6,023
-298
| -5% | -$48.7K | ﹤0.01% | 657 |
|
|
2017
Q4 | $948K | Buy |
6,321
+200
| +3% | +$29.6K | ﹤0.01% | 698 |
|
|
2017
Q3 | $931K | Buy |
6,121
+19
| +0.3% | +$2.86K | ﹤0.01% | 677 |
|
|
2017
Q2 | $786K | Sell |
6,102
-163
| -3% | -$19.6K | ﹤0.01% | 732 |
|
|
2017
Q1 | $685K | Buy |
6,265
+774
| +14% | +$68.1K | ﹤0.01% | 725 |
|
|
2016
Q4 | $405K | Sell |
5,491
-1,907
| -26% | -$155K | ﹤0.01% | 852 |
|
|
2016
Q3 | $645K | Sell |
7,398
-207
| -3% | -$19.6K | ﹤0.01% | 702 |
|
|
2016
Q2 | $654K | Buy |
7,605
+3,577
| +89% | +$309K | ﹤0.01% | 676 |
|
|
2016
Q1 | $321K | Buy |
+4,028
| New | +$364K | ﹤0.01% | 816 |
|
|
2014
Q2 | – | Sell |
-9,181
| Closed | -$649K | – | 1005 |
|
|
2014
Q1 | $649K | Buy |
9,181
+966
| +12% | +$76.5K | ﹤0.01% | 618 |
|
|
2013
Q4 | $610K | Buy |
8,215
+4,765
| +138% | +$332K | ﹤0.01% | 606 |
|
|
2013
Q3 | $262K | Buy |
3,450
+25
| +0.7% | +$1.99K | ﹤0.01% | 746 |
|
|
2013
Q2 | $274K | Buy |
+3,425
| New | +$252K | ﹤0.01% | 714 |
|
Other funds holding VRTX
VCM
VPM
Brown Advisory's VRTX Position: Q1 2026 in Review
Brown Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, selling an estimated $56.4K and leaving 7,653 shares worth $3.42M. The position accounts for 0.01% of the portfolio, ranked #591.
Brown Advisory first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. The position peaked at $3.52M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Brown Advisory held 7,653 shares of Vertex Pharmaceuticals worth $3.42M as of Q1 2026.
- Brown Advisory sold 121 Vertex Pharmaceuticals shares in Q1 2026, an estimated $56.4K.
- Vertex Pharmaceuticals made up 0.01% of Brown Advisory's portfolio in Q1 2026, its #591 holding.
- Brown Advisory first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Brown Advisory's Vertex Pharmaceuticals position peaked at $3.52M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.